P957: AN INDIRECT COMPARISON OF ELRANATAMAB’S (ELRA) OBJECTIVE RESPONSE RATE (ORR) FROM MAGNETISMM-3 (MM-3) VERSUS REAL-WORLD EXTERNAL CONTROL ARMS IN TRIPLE-CLASS REFRACTORY (TCR) MULTIPLE MYELOMA (MM)

• Luciano Costa,
• Thomas W Leblanc,
• Hans Tesch,
• Pieter Sonneveld,
• Ryan Kyle,
• Liliya Sinyavskaya,
• Patrick Hlavacek,
• Aster Meche,
• Jinma Ren,
• Alex Schepart,
• Didem Aydin,
• Marco Dibonaventura

Affiliations

Luciano Costa

1 University of Alabama at Birmingham, Birmingham, United States

Thomas W Leblanc

2 Duke University School of Medicine, Durham, United States

Hans Tesch

3 Bethanien Hospital, Frankfurt, Germany

Pieter Sonneveld

4 Erasmus University, Rotterdam, The Netherlands

Ryan Kyle

5 Statlog, Montreal, Canada

Liliya Sinyavskaya

5 Statlog, Montreal, Canada

Patrick Hlavacek

6 Pfizer Inc, New York, United States

Aster Meche

6 Pfizer Inc, New York, United States

Jinma Ren

7 Pfizer Inc, Collegeville, United States

Alex Schepart

6 Pfizer Inc, New York, United States

Didem Aydin

6 Pfizer Inc, New York, United States

Marco Dibonaventura

6 Pfizer Inc, New York, United States